Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Oslo, November 28, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announces that Aitana Peire, Ph.D., has...
-
Oslo, 21 November 2023, a closely related party of Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 500 shares in the company at an average price of NOK...
-
Oslo, 13 November 2023, Ultimovacs ASA (the "Company") refers to the announcement published on 9 November 2023 regarding the issuance of new shares in connection with the Company's employee incentive...
-
Oslo, 09 November 2023, the Board of Directors of Ultimovacs ASA (the "Company") has resolved to increase the Company's share capital by NOK 960 through the issuance of 9,600 new shares, each with a...
-
Oslo, 8 November 2023, Jónas Einarsson, a primary insider and chair of the board of the Company, has today bought 5,300 shares in the company at an average price of NOK 93.95 per share. Following this...
-
Oslo, November 8, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its third quarter 2023 results today. ...
-
Oslo, November 2, 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, invites to a webcast presentation of its third...
-
The supplementary study to INITIUM is designed to provide in-depth data on the biological activity and mode of action of the vaccine-induced T cells, to support the next stages of...
-
Patients in the INITIUM study are taking longer than expected to experience cancer progression. Reaching the number of progressing patients required for readout may take several months or even...
-
NON-REGULATORY PRESS RELEASE Oslo, October 25, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announces that...